← Human Trials & Peer-Reviewed Studies
Continuous subcutaneous administration of teriparatide as a therapeutic option in chronic hypoparathyroidism: retrospective study in three tertiary care centers of the epi-hypo study
Plain-language guide to PMID 41439459 (2026): observational study study of Teriparatide.
Key Facts
- PMID
- 41439459
- Journal
- European journal of endocrinology
- Year
- 2026
- Study type
- Observational Study
- Authors
- Attia A et al. (9 authors)
- DOI
- 10.1093/ejendo/lvaf257
What This Study Did, in Plain Language
What Was Tested
Researchers studied Teriparatide in this observational study publication.
The aim of this study was to assess the evolution of biological parameters with CSAT in comparison to previous treatment.
Why It Was Studied
Chronic hypoparathyroidism (cHP) is a rare endocrine disorder characterized by hypocalcemia secondary to the insufficient secretion of the parathyroid hormone.
Despite the good observance of oral treatment with calcium salts and active vitamin D analogs, and even after adding intermittent subcutaneous injections of teriparatide (IST), some patients are still uncontrolled.
Who Took Part
PubMed indexes the participants as adults, middle-aged adults and older adults, both men and women.
Retrospective observational study including all patients who received CSAT from 3 tertiary care centers of the Epi-Hypo study.
Blood calcium, phosphate, bone remodeling markers, urine calcium, and the evolution of oral treatment were captured from electronic medical records.
How the Study Was Run
Quality of life (QoL) was assessed using the Hypoparathyroid Patient Questionnaire (HPQ28).
What Was Measured
Chronic hypoparathyroidism (cHP) is a rare endocrine disorder characterized by hypocalcemia secondary to the insufficient secretion of the parathyroid hormone.
PubMed files the paper under topics including Hypoparathyroidism, Teriparatide, Tertiary Care Centers, Bone Density Conservation Agents, Calcium, Quality of Life and Chronic Disease.
Author keywords: chronic hypoparathyroidism, hypocalcemia and pump.
What This Means in Plain Language
This is a observational study of Teriparatide.
Results are reported in around 6 sentences of the abstract; we leave them to the paper itself rather than summarise them.
The publication is from 2026 (European journal of endocrinology), a journal based in England.
More context: the Teriparatide compound page, all human trials.
Our Notes on the Compound
Teriparatide: A parathyroid hormone fragment, PTH(1-34), with human trials and approved-pen labeling; the research vial is not the approved pen.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.